Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, 외. (2019년 7월 26일). “Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach”. 《Expert Review of Gastroenterology & Hepatology》 13 (8): 731–738. doi:10.1080/17474124.2019.1645595. ISSN1747-4124. PMID31322440.
Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I (2005년 7월 20일). “Adalimumab for treating rheumatoid arthritis.”. 《The Cochrane Database of Systematic Reviews》 (3): CD005113. doi:10.1002/14651858.CD005113.pub2. PMID16034967.
Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R (2019년 7월 3일). “VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand”. 《Current Medical Research and Opinion》 35 (10): 1837–1846. doi:10.1080/03007995.2019.1634952. ISSN0300-7995. PMID31233347. S2CID195354397.
Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, 외. (January 2008). “Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial”. 《J. Am. Acad. Dermatol.》 58 (1): 106–15. doi:10.1016/j.jaad.2007.09.010. PMID17936411.
Maarouf M, Clark AK, Lee DE, Shi VY (August 2018). “Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials”. 《J Dermatolog Treat》 29 (5): 441–449. doi:10.1080/09546634.2017.1395806. PMID29098911. S2CID39246564.
Horneff G, Seyger MM, Arikan D, Kalabic J, Anderson JK, Lazar A, 외. (October 2018). “Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease”. 《J. Pediatr.》 201: 166–175.e3. doi:10.1016/j.jpeds.2018.05.042. PMID30054164.
Correll CK, Bullock DR, Cafferty RM, Vehe RK (February 2018). “Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis”. 《Clin. Rheumatol.》 37 (2): 549–553. doi:10.1007/s10067-017-3890-4. PMID29103180. S2CID20099281.
Hochman D, Wolff B (November 2006). “Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis”. 《JAMA》 296 (18): 2203; author reply 2203–4. doi:10.1001/jama.296.18.2203-a. PMID17090763.
Chen, Yuehong; Friedman, Marcia; Liu, Gang; Deodhar, Atul; Chu, Cong-Qiu (2018). “Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?”. 《Cytokine》 101: 78–88. doi:10.1016/j.cyto.2016.09.013. ISSN1043-4666. PMID27688201. S2CID20837188.지원되지 않는 변수 무시됨: |name-list-style= (도움말)
World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). 《World Health Organization model list of essential medicines: 22nd list (2021)》. Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, 외. (2019년 7월 26일). “Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach”. 《Expert Review of Gastroenterology & Hepatology》 13 (8): 731–738. doi:10.1080/17474124.2019.1645595. ISSN1747-4124. PMID31322440.
Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I (2005년 7월 20일). “Adalimumab for treating rheumatoid arthritis.”. 《The Cochrane Database of Systematic Reviews》 (3): CD005113. doi:10.1002/14651858.CD005113.pub2. PMID16034967.
Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R (2019년 7월 3일). “VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand”. 《Current Medical Research and Opinion》 35 (10): 1837–1846. doi:10.1080/03007995.2019.1634952. ISSN0300-7995. PMID31233347. S2CID195354397.
Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, 외. (January 2008). “Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial”. 《J. Am. Acad. Dermatol.》 58 (1): 106–15. doi:10.1016/j.jaad.2007.09.010. PMID17936411.
Maarouf M, Clark AK, Lee DE, Shi VY (August 2018). “Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials”. 《J Dermatolog Treat》 29 (5): 441–449. doi:10.1080/09546634.2017.1395806. PMID29098911. S2CID39246564.
Horneff G, Seyger MM, Arikan D, Kalabic J, Anderson JK, Lazar A, 외. (October 2018). “Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease”. 《J. Pediatr.》 201: 166–175.e3. doi:10.1016/j.jpeds.2018.05.042. PMID30054164.
Correll CK, Bullock DR, Cafferty RM, Vehe RK (February 2018). “Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis”. 《Clin. Rheumatol.》 37 (2): 549–553. doi:10.1007/s10067-017-3890-4. PMID29103180. S2CID20099281.
Hochman D, Wolff B (November 2006). “Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis”. 《JAMA》 296 (18): 2203; author reply 2203–4. doi:10.1001/jama.296.18.2203-a. PMID17090763.
Chen, Yuehong; Friedman, Marcia; Liu, Gang; Deodhar, Atul; Chu, Cong-Qiu (2018). “Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?”. 《Cytokine》 101: 78–88. doi:10.1016/j.cyto.2016.09.013. ISSN1043-4666. PMID27688201. S2CID20837188.지원되지 않는 변수 무시됨: |name-list-style= (도움말)
Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R (2019년 7월 3일). “VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand”. 《Current Medical Research and Opinion》 35 (10): 1837–1846. doi:10.1080/03007995.2019.1634952. ISSN0300-7995. PMID31233347. S2CID195354397.
Maarouf M, Clark AK, Lee DE, Shi VY (August 2018). “Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials”. 《J Dermatolog Treat》 29 (5): 441–449. doi:10.1080/09546634.2017.1395806. PMID29098911. S2CID39246564.
Correll CK, Bullock DR, Cafferty RM, Vehe RK (February 2018). “Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis”. 《Clin. Rheumatol.》 37 (2): 549–553. doi:10.1007/s10067-017-3890-4. PMID29103180. S2CID20099281.
Chen, Yuehong; Friedman, Marcia; Liu, Gang; Deodhar, Atul; Chu, Cong-Qiu (2018). “Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?”. 《Cytokine》 101: 78–88. doi:10.1016/j.cyto.2016.09.013. ISSN1043-4666. PMID27688201. S2CID20837188.지원되지 않는 변수 무시됨: |name-list-style= (도움말)
Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R (2019년 7월 3일). “VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand”. 《Current Medical Research and Opinion》 35 (10): 1837–1846. doi:10.1080/03007995.2019.1634952. ISSN0300-7995. PMID31233347. S2CID195354397.
Chen, Yuehong; Friedman, Marcia; Liu, Gang; Deodhar, Atul; Chu, Cong-Qiu (2018). “Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?”. 《Cytokine》 101: 78–88. doi:10.1016/j.cyto.2016.09.013. ISSN1043-4666. PMID27688201. S2CID20837188.지원되지 않는 변수 무시됨: |name-list-style= (도움말)